U.S. Research ELISA Markets

This Frost & Sullivan research service titled U.S. Research ELISA Markets provides revenue forecasts for the overall market. It provides in-depth analyses of market-wide and segment-specific drivers, restraints, and challenges, with the corresponding strategic recommendations. In this research, Frost & Sullivan's expert analysts thoroughly examine the following research ELISA markets: kits and development components.

Market Overview

Research ELISA’s Established Credentials Help it Weather Competition from Multiplex Proteomic Arrays

After a glorious 37-year run as a reliable and trusted technology for analyte quantitation, the research enzyme-linked immunosorbent assay (ELISA) technique has reached market maturity. It is drawing on its entrenched reputation for quality results and reproducibility to stave off the challenge mounted by newer multiplex proteomic array technologies. This new-age technology scores over the single-analyte quantitation technique of ELISA by offering high throughput capability and allowing researchers to measure multiple analytes simultaneously.

"While the increased use of multiplex proteomic array technologies has stalled the research ELISA market, new ELISA products remain profitable at the provider level," says the analyst of this research service. "Market participants are discovering that many laboratories still prefer the ELISA technique or continue using the technology for secondary validation after multiplexing." ELISA suppliers can also position their products as the ideal tools for researchers that do not need the advantages of multiplexing, focus only on a few analytes, and require high assay sensitivity. This strategy can help diffuse the threat of price instability, which is consequent to the commoditization of products for popular analytes.

With over 60 participants serving in the ELISA market, it is vital to focus new products on areas of research where multiplex arrays have not been developed. "Many providers are expected to slow the expansion of their ELISA portfolios or focus on niche markets and unique species to circumvent growing competition from proteomic arrays," observes the analyst. "ELISA providers must adapt their strategies to complement multiplex platforms rather than try to compete head-on." Increasingly, companies have opted to develop their own multiplex assay portfolios to take advantage of the new technology and expand customer options.